ophthalmologytimes18 天
Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN ...
In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...